Fig. 6: MSLN activates the EGFR-ERK1/2 signaling pathway.
From: MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer
A Venn diagram illustrating potential interacting proteins of MSLN, including those identified by LC–MS/MS and those predicted through String databases. The direct interaction between MSLN and EGFR in HCC1806/HM3 (B) and 4T1/HM3 cells was verified by Co-IP assays (C) using anti-MSLN and anti-EGFR antibodies. D IF co-staining was performed to show the co-localization of MSLN (Green) and EGFR (Red) in HCC1806/HM3 and 4T1/HM3 cells. E Molecular docking demonstrates the best docking panel of MSLN (Blue) and EGFR (Green) proteins. F Significant GO clusters for the Biological Process categories enriched by the DEGs between MSLN-knockdown HCC1806/HM3 cells and control cells. G Western blotting to check the expression of the key factors of the EGFR-ERK1/2 signaling in cells with MSLN knockdown cells (HCC1806/HM3 and 4T1/HM3, left panels) and overexpression cells (HCC1806/Pri and 4T1/Pri, right panels) (#, MSLN). H Western blot analysis and quantification of EGFR dimerization levels in treated cells (n = 3). (Data are presented as the mean ± SD; ns no statistical difference, *P < 0.05, ** P < 0.01, ***P < 0.001).
